Market Overview

Isis Pharma Issues Update on CHMP Opinion on KYNAMRO

Related ISIS
Benzinga's Top Initiations
Isis Pharma 8-K Filing Shows Company Enters Agreement with Astrazeneca To Discover And Develop Antisense Drugs FOr Cardiovascular, Metabolic And Renal Disease

Isis Pharmaceuticals Inc. (NASDAQ: ISIS) today announced that following Genzyme's request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) confirmed its previous position and has maintained a negative opinion regarding the marketing authorization application (MAA) for KYNAMRO^TM (mipomersen) as a treatment for patients with Homozygous Familial Hypercholesterolaemia (HoFH).

The FDA approved KYNAMRO in the United States in January 2013 for the treatment of patients with Homozygous Familial Hypercholesterolaemia.

Posted-In: News


Related Articles (ISIS)

Get Benzinga's Newsletters